BioAge Labs, Inc.
BIOA
$10.29
$1.0711.61%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.41M | 1.45M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.05M | 2.41M | 1.45M | -- | -- |
| Cost of Revenue | 18.51M | 19.84M | 11.11M | -- | 20.02M |
| Gross Profit | -16.46M | -17.43M | -9.66M | -- | -20.02M |
| SG&A Expenses | 6.68M | 7.34M | 6.79M | 6.14M | 4.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.19M | 27.18M | 17.90M | 25.36M | 24.75M |
| Operating Income | -23.14M | -24.77M | -16.45M | -25.36M | -24.75M |
| Income Before Tax | -20.17M | -21.56M | -12.93M | -21.13M | -23.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.17M | -21.56M | -12.93M | -21.13M | -23.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.17M | -21.56M | -12.93M | -21.13M | -23.41M |
| EBIT | -23.14M | -24.77M | -16.45M | -25.36M | -24.75M |
| EBITDA | -23.09M | -24.71M | -16.41M | -25.32M | -24.71M |
| EPS Basic | -0.56 | -0.60 | -0.36 | -0.59 | -6.70 |
| Normalized Basic EPS | -0.35 | -0.38 | -0.23 | -0.37 | -4.19 |
| EPS Diluted | -0.56 | -0.60 | -0.36 | -0.59 | -6.70 |
| Normalized Diluted EPS | -0.35 | -0.38 | -0.23 | -0.37 | -4.19 |
| Average Basic Shares Outstanding | 35.85M | 35.85M | 35.85M | 36.01M | 3.49M |
| Average Diluted Shares Outstanding | 35.85M | 35.85M | 35.85M | 36.01M | 3.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |